Creatd Divests Flyte for $11.55M; Selling Stockholders Offer 180K Shares
Creatd, Inc. filed an S-1 registration statement for the resale of up to 180,030 shares of common stock by selling stockholders, from which the company will not receive direct proceeds. A significant recent development is the sale of its 80.02% equity interest in Fly Flyte, Inc. to Catheter Precision, Inc. for $11,554,827 in cash and preferred stock on March 8, 2026. The company also completed an uplist financing in November 2025, raising funds through convertible notes and warrants, though remaining tranches were released after the Flyte divestment. Creatd has undergone multiple reverse stock splits, including a 1-for-20 split in February 2026 and a 1-for-500 split in January 2024, and reported a net loss of $9.4 million for the year ended December 31, 2025, with ongoing going concern doubts.
Key Highlights
- Creatd sold its 80.02% equity interest in Fly Flyte, Inc. for $11,554,827 on March 8, 2026.
- Consideration for the divestment included $5,776,827 cash and $5,778,000 in VTAK Preferred Series D Stock.
- Selling stockholders are offering up to 180,030 shares of common stock for resale via this S-1 filing.
- The company completed an uplist financing in November 2025, raising funds through convertible notes and warrants.
- Creatd implemented a 1-for-20 reverse stock split on February 24, 2026.
- The company reported a net loss of $9.4 million for the year ended December 31, 2025.
- Creatd has a working capital deficit of $7.9 million and an accumulated deficit of $262.9 million.
- Common stock trades on OTCQB under "CRTD" and was priced at $3.37 on July 30, 2026.
Price Impact
More from CRTD